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were anaphylaxis (n = 6), urticaria (n = 9) and urticaria-angio-
edema (n = 3). The median time interval between the reac-
tion and the study was 225 days (interquartile range, IQR: 
120–387.5) and between drug intake and the development 
of symptoms 30 min (IQR: 6.25–30). We obtained similar data 
for both the direct and passive HRT, with a sensitivity and 
specificity of 55 and 85%, respectively, a positive predictive 
value of 76% and a negative predictive value of 69%.  Conclu-
sions: The sensitivity of both the direct and passive HRT for 
diagnosing patients with immediate allergy to CLV is less 
than 60%. However, the passive HRT has the advantage that 
it is based on the testing of serum samples that can be han-
dled more easily than fresh blood samples. 
 © 2016 S. Karger AG, Basel 
 Introduction 
 β-Lactam (BL) antibiotics are still the most frequently 
used drugs causing IgE-mediated allergic reactions  [1–4] . 
Although all BLs can be involved in these reactions, cur-
rently amoxicillin (AX), and to a lesser extent cephalo-
 Key Words 
 Allergy · Clavulanic acid · Diagnosis · Histamine release · 
Immediate reactions 
 Abstract 
 Background: Immediate hypersensitivity reactions to clavu-
lanic acid (CLV) seem to be on the increase. Diagnosis is 
mainly based on skin testing and the drug provocation test 
(DPT), procedures that are not risk free. The aim of this study 
was to evaluate whether the histamine release test (HRT) 
could help evaluate patients with selective hypersensitivity 
to CLV.  Methods: Eighteen patients with immediate selec-
tive hypersensitivity reactions to CLV (positive skin tests to 
CLV but negative to the major and minor determinants of 
benzylpenicillin and amoxicillin; negative DPT to benzylpen-
icillin and amoxicillin) and 21 controls with tolerance to CLV 
were included. Direct and passive HRT, using patient whole 
blood or ‘IgE-stripped’ donor blood sensitized by patient se-
rum, respectively, were performed by stimulating the blood 
with CLV, and basophil histamine release was detected by 
fluorometric determination.  Results: The clinical symptoms 
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sporins, are the most frequently involved  [1–4] . AX can 
induce selective reactions in a large proportion of cases, 
implying that patients can react to AX but tolerate ben-
zylpenicillin (BP)  [5–7] . Immunochemical studies per-
formed in these patients have shown that although side-
chain chemical structures are the most important for im-
munological recognition and clinical response, part of the 
common BL structure is also required for optimal recog-
nition  [8] .
 Today, AX is often used in combination with clavu-
lanic acid (CLV), a β-lactamase inhibitor. Although CLV 
was initially considered a non-immunogenic compound 
due to its chemical instability  [9] , it has now been report-
ed that CLV can generate stable products from an inter-
mediate structure  [10] that may be involved in IgE recog-
nition  [9] and induce hypersensitivity reactions  [7, 11–
14] . Moreover, this tendency is thought to be on the 
increase as it has been shown that patients with selective 
reactions to CLV are younger than those with selective 
reactions to AX, probably reflecting changes in consump-
tion patterns  [13] . Therefore, the evaluation of immediate 
hypersensitivity reactions to AX-CLV is more complex 
since either AX or CLV can cause allergic reactions.
 The diagnosis of selective reactions to CLV is mainly 
based on skin testing with this compound or by the drug 
provocation test (DPT), both of which are time-consum-
ing and not free of risk. Moreover, in order to demon-
strate a selective reaction to CLV, tolerance to BP and AX 
has to be confirmed by DPT. Among the in vitro tests 
used to confirm selective reactions to CLV, only studies 
using the basophil activation test (BAT) have shown 
promising results  [12–14] .
 Another in vitro test is the histamine release test (HRT) 
using human basophils. This has been used to diagnose 
IgE-mediated reactions with variable results and techni-
cal difficulties mainly related to the large blood volume 
required, the kinetics of histamine release and the diffi-
culty of detecting histamine levels using chromatogra-
phy, fluorescence and immunoassay methods  [15] .  More-
over, to achieve a high sensitivity leukocyte enrichment 
may be required  [16, 17] . To solve these issues, a simpli-
fied method based upon selective binding of histamine to 
glass microfibres has been developed to measure basophil 
histamine release in IgE-mediated allergic patients with 
high sensitivity and with a reduced preparation time  [18] . 
This test provides several advantages since the isolation 
of cells and the extraction of histamine is not necessary, 
making the method suitable for routine diagnosis  [19, 
20] . Previously, HRT has mainly been used for experi-
mental purposes  [21, 22] .
 In this study, we used the HRT to analyse the role of 
histamine release for evaluating immediate allergic reac-
tions to CLV in a well-characterized group of patients 
with skin test positivity to CLV.
 Subjects and Methods 
 Patient Selection 
 The study group comprised 18 patients diagnosed with imme-
diate allergic reactions (appearing less than 1 h after drug admin-
istration), selective to CLV and with skin test positivity to CLV. 
Patients were selected from those with a history of immediate al-
lergic reactions to AX-CLV in the allergy units of four Spanish 
hospitals during 2013. For diagnosis, we followed the European 
Academy of Allergy and Clinical Immunology general guidelines 
for the evaluation of immediate reactions to BLs  [23] . Selective re-
actors to CLV were chosen based on positive skin test results to 
CLV and no reaction to BP and AX in the DPT. The clinical enti-
ties presented by the patients were classified as urticaria, urticaria-
angioedema or anaphylaxis, as described  [2] . A control group 
comprising 21 healthy individuals who had previously received 
AX-CLV without any adverse effects and who gave negative skin 
test results to CLV was also included. Relevant institutional review 
boards approved the study and informed consent was obtained 
from all subjects.
 Skin Testing 
 Skin testing was performed by prick, and if negative followed 
by intradermal testing as recommended  [7, 23] . The maximum 
concentrations used were as follows: benzylpenicilloyl octa- L - 
lysine (PPL) 0.04 mg/ml, with a molar concentration of the ben-
zylpenicilloyl moiety of 8.64 × 10 –5  M , minor determinant (DM) 
0.5 mg/ml, with a molar concentration of the sodium benzylpenil-
loate of 1.5 × 10 –3  M , AX 20 mg/ml and CLV 20 mg/ml (DIATER 
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 Fig. 1. Dose-response study for determining the highest concen-
tration of CLV that did not induce unspecific histamine release 
(>10 ng/ml of histamine). 
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Laboratories, Madrid, Spain). In those cases with a history of se-
vere anaphylaxis, we performed the test with increasing dilutions 
until the maximum concentration was reached, as described else-
where  [23] . In the skin prick tests, a wheal larger than 3 mm with 
a negative response to the control saline was considered positive. 
In the intradermal tests, the wheal area was marked initially and 
20 min after testing, and an increase in diameter greater than 3 mm 
was considered positive.
 Drug Provocation Test 
 To confirm selective reactions to CLV, a single-blind, placebo-
controlled DPT was performed with BP, penicillin V (PV) and AX 
in patients with negative skin tests to PPL, DM and AX, as report-
ed  [23] . Briefly, a DPT with BP was performed by parenteral route 
in a single dose of 10 6 units, followed by a 3-day therapeutic course 
of PV of 500 mg/8 h, when PPL and DM in the skin test were neg-
ative. If the DPT with BP and PV was negative and the skin test was 
negative to AX, a DPT with AX was performed. For this, incremen-
tal doses of AX were administered, with 30-min time intervals un-
til reaching a cumulative dose of 500 mg, followed by a 3-day ther-
apeutic course of AX 500 mg/8 h.
 Direct HRT 
 The direct HRT was performed according to the method de-
scribed by Stahl-Skov et al.  [18, 19] . Briefly, whole blood samples 
were collected in heparinized tubes from patients and controls. 
These were centrifuged and plasma was removed and replaced 
by the same volume of PIPES buffer: 10 m M piperazine-N,N ′ -
bis(ethane sulfonic acid), 140 m M sodium acetate, 5 m M potassium 
acetate, 0.6 m M CaCl 2 , 1.1 m M MgCl 2 , 1 mg/ml glucose, 0.3 mg/ml 
HSA and 15 IU/ml heparin. Afterwards, 25 μl of washed blood in 
the presence of IL-3 (2 ng/ml blood) was incubated in the glass 
fibre-prepared microtiter plates (RefLab, Copenhagen, Denmark), 
with 25 μl of potassium clavulanate (DIATER Laboratories) at 100 
μg/ml for 60 min at 37  °  C. The CLV concentration chosen for this 
test (100 μg/ml) was the highest value that did not lead to unspe-
cific histamine release (>10 ng/ml) in a dose-response curve. This 
level corresponded to the mean + 3 SD of the histamine release 
values measured in 5 non-allergic subjects without a specific stim-
ulus ( fig. 1 ). As a positive control, we used 25 μl of anti-IgE (KPL, 
Gaithersburg, Md., USA) in a concentration of 5 μg/ml as well as 
histamine in concentrations of 0 and 50 ng/ml. After incubation, 
the microtiter plate was washed with H 2 O for 1 min to remove cells 
and interfering substances. Thereafter, 75 μl of NaOH/ortho-
phthalaldehyde (OPA) mixture was added to each well allowing 
glass fibre-bound histamine to be released and coupled to OPA. 
After 10 min the coupling reaction was stopped and histamine-
OPA complexes stabilized by adding 75 μl of 0.59% HClO 4 . Hista-
mine was determined fluorometrically in the HISTAREADER TM 
501 (RefLab). Results were expressed as ng/ml of histamine re-
leased.
 A preliminary calibration step was performed for the HRT us-
ing increasing concentrations of histamine from 0 to 50 ng/ml. The 
coefficients of variation of the method were 3.3 (2.1–4.2) according 
to 0 ng/ml of histamine and 3.1 (1.9–4.6) according to 5–50 ng/ml 
of histamine.
 Table 1.  Clinical and demographic characteristics of the patients, and skin test and HRT results with CLV
Pa-
tient
Age,
years
Sex Reaction Interval
study, days
Interval
reaction, min
 Skin test concentration (wheal diameter, mm) HRT (histamine 
concentration, 
ng/ml)
skin prick test intradermal test direct passive
1 41 F Anaph 150 15 20 mg/ml + (9 × 5) n.d. 14 7
2 60 M Anaph 515 5 – 20 mg/ml + (8 × 7) 0 10
3 61 F Urt-Ang 485 5 – 20 mg/ml + (10 × 12) 3 56
4 69 F Anaph 912 5 – 20 mg/ml + (11 × 10) 10 61
5 31 F Anaph 365 30 – 5 mg/ml + (15 × 12) 15 56
6 67 F Urt 180 60 – 5 mg/ml + (9 × 11) 9 62
7 54 F Urt-Ang 270 10 – 5 mg/ml + (11 × 13) 19 24
8 34 M Anaph 300 30 – 20 mg/ml + (10 × 15) 17 34
9 29 F Anaph 425 30 – 20 mg/ml + (9 × 6) 33 34
10 51 M Urt 110 30 – 0.5 mg/ml + (7 × 9) 7 12
11 53 M Urt 90 60 – 5 mg/ml + (12 × 7) 3 4
12 58 F Urt 170 30 – 5 mg/ml + (11 × 10) 9 4
13 58 M Urt 60 30 20 mg/ml + (11 × 5) n.d. 18 13
14 18 M Urt 120 60 – 5 mg/ml + (17 × 13) 45 39
15 30 F Urt-Ang 90 30 – 0.5 mg/ml + (12 × 10) 19 2
16 30 F Urt 365 2 – 5 mg/ml + (20 × 18) 13 10
17 32 F Urt 395 30 – 5 mg/ml + (21 × 16) 10 9
18 29 M Urt 120 5 – 5 mg/ml + (28 × 16) 12 10
 Interval study: time between the reaction occurrence and the study. Interval reaction: time between drug administration and appear-
ance of the symptoms. Ang = Angioedema; Anaph = anaphylaxis; n.d. = not done; Urt = urticaria.
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 Passive HRT 
 Passive sensitization was performed using heparinized blood 
from a single non-allergic healthy donor, with the following char-
acteristics: (1) a confirmed strong reaction to anti-IgE (histamine 
released: 45 ± 5 ng/ml) and (2) no response to CLV. To remove the 
IgE bound on the basophils surface, 3 ml of blood were treated with 
10 ml of stripping buffer (0.14  M NaCl, 0.005  M KCl and 0.0134  M 
lactic acid) for 10 min at 4   °   C. Then, 0.5 ml of sera from patients 
or controls were incubated with 3 ml of the ‘IgE-stripped’ donor 
blood for 60 min at 37   °   C. Following this, the same protocol de-
scribed for the direct HRT was followed. Stripping experiments 
were controlled by confirming no positive histamine release after 
stimulation of non-sensitized basophils with anti-IgE. Passive sen-
sitization was confirmed when a strong reaction occurred (hista-
mine released: 45 ± 5 ng/ml) once we added the serum of the pa-
tient (sensitized cells) and anti-IgE.
 Statistical Analysis 
 Quantitative variables were described using the median and the 
interquartile range (IQR). Comparisons for variables without a 
normal distribution were carried out using the Mann-Whitney 
test. ROC curve analyses were performed to calculate the optimal 
cut-off value corresponding to the best sensitivity and specificity. 
All reported p values represent two-tailed tests, with values <0.05 
considered statistically significant.
 Results 
 The study included 18 patients with immediate selec-
tive hypersensitivity reactions and positive skin tests to 
CLV. The clinical characteristics and the results of the al-
lergological work-up are shown in  table 1 . The median 
age was 46 years (IQR: 30.25–58), 11 were females, AX-
CLV was the drug involved in all reactions, 9 developed 
urticaria, 3 urticaria-angioedema and 6 anaphylaxis 
(1 had a severe reaction with marked hypotension). The 
median time interval between the reaction and the study 
was 225 days (IQR: 120–387.5) and between drug intake 
and the development of symptoms 30 min (IQR: 6.25–30).
 Skin test results were negative for PPL, DM and AX 
and positive for CLV in all cases. Positivity was obtained 
by a skin prick test in 2 patients at 20 mg/ml and by an 
intradermal test in the remaining 16 patients (2 at 0.5 mg/
ml, 9 at 5 mg/ml and 5 at 20 mg/ml). No patient developed 
systemic symptoms after skin testing. Skin testing (in-
cluding intradermal test) with CLV was negative in all 21 
control subjects.
 For HRT standardization, we first performed a dose-
response study for establishing the highest concentration 
of CLV that did not induce unspecific histamine release, 
corresponding to the mean + 3 SD of background hista-
mine release values measured in 5 non-allergic subjects 
( fig. 1 ). We found 100 μg/ml of CLV to be the best con-
centration for the test. ROC curve analyses were per-
formed to determine the optimal cut-off value for consid-
ering positive results. The results showed values >11 ng/
ml of histamine to be the optimal cut-off for both the di-
rect and passive HRT ( fig. 2 ).
 Considering HRT results ( table 1 ) there were 10 (55%) 
positive cases in the direct HRT and 10 (55%) positive 
cases in the passive HRT, with 14 (77%) cases being posi-
tive to at least one test. The sensitivity and specificity of 
both the direct and passive HRT was 55 and 85%, respec-
tively, with a positive predictive value of 76% and a nega-
tive predictive value of 69%.
 Comparisons of the median values of released hista-
mine for the direct and passive HRT in patients versus 
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 Fig. 2. ROC curve generated after comparison of direct and passive 
HRT to CLV of allergic vs. non-allergic subjects. 
Cut-off Sensitivity, % Specificity, %
Direct HRT
>7.500 82.35 66.67
>8.500 82.35 76.19
>9.500 70.59 76.19
>11.00 58.82 85.71
>12.50 52.94 90.48
>13.50 47.06 90.48
>14.50 41.18 90.48
Passive HRT
>7.500 77.78 61.90
>8.500 77.78 76.19
>9.500 72.22 76.19
>10.50 55.56 80.95
>11.50 55.56 85.71
>12.50 50.00 85.71
>18.50 44.44 90.48
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controls are shown in  figure 3 . Data showed significant 
differences between patients and controls in both the di-
rect (p = 0.0052) and passive HRT (p = 0.0030). No dif-
ferences were observed in the concentration of histamine 
released when comparing the direct and passive HRT 
(data not shown).
 There was a positive correlation between histamine re-
lease levels obtained with the direct and passive HRT 
(p = 0.0031; Spearman’s r = 0.4670;  fig. 4 ). No correlation 
was found between the histamine release and the time in-
terval between the reaction and the study, or between the 
drug intake and the development of symptoms or with 
the concentration of CLV required to produce a positive 
skin test.
 Discussion 
 BL allergy is self-reported by at least 10% of patients, 
although only 10% of these are truly allergic  [24] . A diag-
nosis of BL allergy in hospitalized patients, whether con-
firmed or not, is a treatment disadvantage as it increases 
the risk of bacterial resistance, the number of days spent 
at hospital, the risk of opportunistic infections and the 
cost to the health system  [25, 26] .  Therefore, it has recent-
ly been claimed that BL allergy is a public health problem, 
particularly complicated by changes in the consumption 
of these antibiotics  [27] . In fact, AX in combination with 
CLV is now the most frequently consumed BL in many 
countries, and therefore selective allergic reactions to CLV 
are becoming increasingly prevalent in children  [28] and 
adults  [11–14] .  Moreover, it has recently been shown that 
CLV selective responses are not modified by exposure to 
penicillin determinants, indicating that these patients can 
take penicillin derivatives safely  [7] . Therefore, perform-
ing an accurate diagnosis of BL allergy is mandatory. 
However, the methods available nowadays, such as skin 
testing and DPT, are time-consuming, need qualified 
medical staff and are not risk free  [23, 29] . In the recent 
International Consensus on Drug Allergy  [30] , the need 
for discriminating biological tests to establish the nature 
of culprit agents was highlighted, particularly for patients 
receiving several drugs simultaneously, and for severely 
life-threatened patients when skin tests are negative or not 
possible, and the DPT is contraindicated. To this end, we 
have performed an evaluation of HRT for the first time in 
patients with confirmed immediate allergic reactions to 
CLV and positive skin tests, and we found that more than 
half of these cases gave positive results.
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 Fig. 4. Scatter graph showing the positive correlation between his-
tamine release levels obtained with the direct and passive HRT. 
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 The HRT was described in the last century. However, it 
has achieved limited use because it was originally time-
consuming, only few patients could be tested per day and 
its sensitivity for diagnosing drug allergy was unknown 
 [15] . This test has been simplified and its sensitivity has 
been improved using glass microfibre plates to which his-
tamine is specifically bound  [18] – this allows performing 
the tests in any laboratory independently of equipment 
availability and sending them to a reference laboratory. 
The advantages of the system are: (1) patient blood is test-
ed in a number of drug concentrations from 6 to 12, (2) up 
to 10 drugs can be tested on the same HRT plate and (3) 
heparinized blood can be stored and shipped at room tem-
perature for up to 36 h before testing. Moreover, the pas-
sive HRT allows performing the test only by sending sera.
 We found in this study that the sensitivity of the direct 
HRT was 55% and the specificity 85%. These results were 
similar to those found for the BAT in another study with 
16 selective allergic patients to CLV with positive skin 
tests to CLV, in which 50% of the patients had positive 
results for the BAT  [13] . These results indicate that the 
direct HRT and the BAT could be broadly equivalent in 
in vitro tests in terms of results, although comparative 
studies in the same group of patients must be performed 
to compare these techniques directly.
 However, both the direct HRT and the BAT have the 
disadvantage of being cellular tests that need to be per-
formed 24–48 h after drawing blood, meaning samples 
cannot be stored, so the test should be performed close to 
the blood collection place. These drawbacks could be 
avoided by using a passive sensitization of basophils from 
donors with serum IgE from patients. This method has 
been previously used to evaluate the functional character-
istics of IgE in patients  [31, 32] . However, the passive BAT 
has not shown positive results for evaluating drug hyper-
sensitivity reactions. In the present study we have per-
formed the direct and passive HRT with samples from the 
same patients and found similar results for both, with a 
sensitivity of 55% and a specificity of 85% for both test 
types. Both tests had similar ROC curves, the same cut-off 
point and a positive correlation, indicating that the results 
obtained with the two tests showed equivalent sensitivities 
and specificities. However, the direct and passive HRT 
were positive in different patients, and when the two tests 
were combined, the number of positive cases increased 
from 55 to 78%. There might be several explanations for 
the differences observed. In the direct HRT, false-negative 
results might be due to either non-responding basophils 
due to impaired IgE signalling or low histamine content in 
basophils beyond the detection limit of the HRT system.
 In the passive HRT, these limitations can be overcome 
because donor cells are selected on the basis of high IgE 
responsiveness and sufficient basophil histamine con-
tent. However, false-negative results can occur if the level 
of specific IgE in serum is low  [32] .
 These results are interesting because, as far as we know, 
this is the first study showing a positive diagnostic out-
come among a large group of patients using passive sen-
sitization and basophil stimulation in drug hypersensi-
tivity. Although one of the main challenges of using the 
passive HRT is to have access to a donor with highly
responding basophils, the use of a single donor, on the 
other hand, allows a significant reduction of the inter-
individual variability due to the basophil releasability.
 In fact, in the present study all the passive tests were 
done with basophils obtained from the same donor. It is 
important to take into account that the passive sensitiza-
tion of stripped basophils is the only way to report that 
the basophil histamine release induced by a drug is medi-
ated by specific IgE.
 Finally, regarding patients included in the study, it is of 
note that, as reported in other studies  [13] , they were gen-
erally young subjects and 1/3 of them developed anaphy-
laxis. We did not detect any correlation in the time inter-
val between the clinical reaction and the performance of 
the HRT. This contrasts with results observed in a study 
with selective patients to AX tested with the BAT, where 
the positive outcome of the BAT was inversely correlated 
to the time interval after the clinical reaction  [33] . How-
ever, studies with larger numbers of patients are needed to 
confirm this possibility. Considering skin testing, 2 pa-
tients were diagnosed by prick test, and only 5 patients 
needed to reach the maximum concentration of the re-
agent in the intradermal test (20 mg/ml) to obtain a posi-
tive result. No correlation was obtained between the skin 
test and the HRT results. The present study does not in-
clude patients with a skin test negative to CLV but DPT 
positive, and therefore it is not possible to evaluate the 
outcome of the HRT in this group of patients.
 In conclusion, we have shown in this study that the 
HRT can be a promising in vitro method for the evalua-
tion of patients with immediate selective reactions to 
CLV, including patients where skin prick testing or prov-
ocations cannot be performed due to the risk of systemic 
reactions. Moreover, the passive HRT has been shown to 
be equivalent to the direct HRT in terms of performance, 
with the advantage that only patient sera are needed. Al-
though these results should be reproduced in a larger 
group of patients, this study opens an area of research into 
the utility of the HRT for the diagnosis of allergy to other 
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BLs and in patients who are skin test negative but DPT 
positive. Furthermore, it is important to carry out com-
parative studies between the HRT and other in vitro tests, 
such as the BAT.
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